AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31286428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers for subsidized early childcare
Number of subjects: 0
Study 28118280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 51
Study 28118280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25905845 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative film
Number of subjects: 704
Study 25905845 — intervention group
Group type: COMPARATOR
Intervention: Nonnarrative film
Number of subjects: 704
Study 23667467 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen combined with medroxyprogesterone acetate therapy
Number of subjects: 38908
Study 23667467 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy alone
Number of subjects: 38908
Study 21380544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HF)
Number of subjects: 8
Study 21380544 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control meal (CON)
Number of subjects: 8
Study 21380544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with exercise (HFE)
Number of subjects: 8
Study 21380544 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control meal with exercise (CONE)
Number of subjects: 8
Study 19894006 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (20-min stimulation session twice daily for 3 weeks)
Number of subjects: 16
Study 19894006 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation
Number of subjects: 16
Study 17159079 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 26
Study 17159079 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 26
Study 15530138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.15 uL/Kg
Number of subjects: 1029
Study 15530138 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 1 mg/kg
Number of subjects: 1029
Study 15530138 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 1029
Study 15530138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 1029
Study 15530138 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction morphine
Number of subjects: 1029
Study 15530138 — intervention group
Group type: COMPARATOR
Intervention: No narcotic
Number of subjects: 1029
Study 14665865 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 1 year (group 1)
Number of subjects: 150
Study 14665865 — intervention group
Group type: COMPARATOR
Intervention: 9 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 3 months (group 2)
Number of subjects: 150
Study 10403729 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical eradication therapy
Number of subjects: 104
Study 10403729 — intervention group
Group type: COMPARATOR
Intervention: OGD
Number of subjects: 104
Study 8524717 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevalence survey
Number of subjects: 1369
Study 8524717 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program combining physician's anti-smoking message with Indian Community Health Representatives' efforts
Number of subjects: 1369
Study 2177997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine and high-fibre dietary advice
Number of subjects: 111
Study 2177997 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine plus ispaghula
Number of subjects: 111
Study 7029236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (SV)
Number of subjects: 0
Study 7029236 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virus vaccine (WVV)
Number of subjects: 0
Study 7029236 — intervention group
Group type: COMPARATOR
Intervention: All three vaccines
Number of subjects: 0
Study 30671796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-Preserving (PP)
Number of subjects: 188
Study 30671796 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-Resecting (PR)
Number of subjects: 188
Study 30335525 — intervention group
Group type: EXPERIMENTAL
Intervention: in vivo exposure therapy (iVET)
Number of subjects: 0
Study 30335525 — intervention group
Group type: COMPARATOR
Intervention: virtual reality exposure therapy (VRET)
Number of subjects: 0
Study 30335525 — intervention group
Group type: COMPARATOR
Intervention: augmented reality exposure therapy (ARET)
Number of subjects: 0
Study 28665534 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS with Indacaterol and Tiotropium (IND/TIO)
Number of subjects: 14
Study 28665534 — intervention group
Group type: COMPARATOR
Intervention: ICS with Indacaterol (IND)
Number of subjects: 14
Study 27620652 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24360745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditto™ intervention
Number of subjects: 75
Study 24360745 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 75
Study 22134475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dietary phenylalanine and tyrosine depletion (APTD)
Number of subjects: 14
Study 22134475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19752552 — intervention group
Group type: EXPERIMENTAL
Intervention: terutroban 10 mg/day
Number of subjects: 48
Study 19752552 — intervention group
Group type: EXPERIMENTAL
Intervention: terutroban 10 mg/day + aspirin 300 mg/day
Number of subjects: 48
Study 19752552 — intervention group
Group type: EXPERIMENTAL
Intervention: clopidogrel 75 mg/day + aspirin 300 mg/day
Number of subjects: 48
Study 19752552 — intervention group
Group type: COMPARATOR
Intervention: aspirin 300 mg/day
Number of subjects: 48
Study 17300633 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Number of subjects: 464
Study 17300633 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine and artesunate (MAS3)
Number of subjects: 464
Study 15134983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once daily plus standard care
Number of subjects: 8113
Study 15134983 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (placebo)
Number of subjects: 8113
Study 12226772 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 8
Study 12226772 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 8
Study 12226772 — intervention group
Group type: COMPARATOR
Intervention: Soft collar
Number of subjects: 8
Study 9659322 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ophthalmoscope
Number of subjects: 98
Study 9659322 — intervention group
Group type: COMPARATOR
Intervention: Slit lamp biomicroscope
Number of subjects: 98
Study 7661882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine treatment
Number of subjects: 5
Study 7661882 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 5
Study 30238302 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR‐RFLP analysis
Number of subjects: 59
Study 30238302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rep‐PCR analysis
Number of subjects: 59
Study 30238302 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical verification
Number of subjects: 59
Study 26881996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment manoeuvres (ARM) and surfactant administration every 8 hours for 3 days
Number of subjects: 31
Study 26881996 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment only
Number of subjects: 31
Study 25307993 — intervention group
Group type: EXPERIMENTAL
Intervention: RIS
Number of subjects: 10
Study 23316699 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP50 (tapentadol hydrochloride extended-release 50 mg)
Number of subjects: 25
Study 23316699 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP250 (tapentadol hydrochloride 250 mg)
Number of subjects: 25
Study 23316699 — intervention group
Group type: COMPARATOR
Intervention: OXY40 (OxyContin® 40 mg)
Number of subjects: 25
Study 23316699 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP50
Number of subjects: 25
Study 23316699 — intervention group
Group type: COMPARATOR
Intervention: OXY40
Number of subjects: 25
Study 23316699 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP250
Number of subjects: 25
Study 20200310 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (2 units/h with 100 ml of 5% dextrose/h for 4 h)
Number of subjects: 10
Study 20200310 — intervention group
Group type: COMPARATOR
Intervention: Dextrose infusion (100 ml of 5% dextrose/h for 4 h)
Number of subjects: 10
Study 20200310 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (100 ml of saline/h for 4 h)
Number of subjects: 10
Study 17979898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (interdisciplinary team of geriatrics specialists)
Number of subjects: 874
Study 17979898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 874
Study 17979898 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 874
Study 15860478 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading aloud and arithmetic calculation training program (2-6 days a week for 6 months)
Number of subjects: 32
Study 15860478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 12173011 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal whole-body insulin sensitivity
Number of subjects: 29
Study 12173011 — intervention group
Group type: EXPERIMENTAL
Intervention: Low whole-body insulin sensitivity
Number of subjects: 29
Study 12173011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 29
Study 12173011 — intervention group
Group type: EXPERIMENTAL
Intervention: LV extent of normoperfused segments with PET-reverse mismatch
Number of subjects: 29
Study 10194648 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 lux in the upper visual field
Number of subjects: 12
Study 10194648 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 lux in the lower visual field
Number of subjects: 12
Study 10194648 — intervention group
Group type: COMPARATOR
Intervention: 5 lux while watching television
Number of subjects: 12
Study 7762775 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (4-5 mg/kg) and enflurane
Number of subjects: 40
Study 7762775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2-2.5 mg/kg) infusion
Number of subjects: 40
Study 7762775 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (IVA)
Number of subjects: 40
Study 7762775 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone/enflurane
Number of subjects: 40
Study 2324538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant virus vaccine (10^7.5 TCID50)
Number of subjects: 66
Study 2324538 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 66
Study 6156074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin
Number of subjects: 0
Study 6156074 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 proactivator
Number of subjects: 0
Study 6156074 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin
Number of subjects: 0
Study 6156074 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen
Number of subjects: 0
Study 6156074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2-macroglobulin
Number of subjects: 0
Study 30962095 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine 100 μg
Number of subjects: 100
Study 30962095 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine 200 μg
Number of subjects: 100
Study 30962095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30962095 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine 100 μg (day regimen)
Number of subjects: 100
Study 30962095 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine 200 μg (month regimen)
Number of subjects: 100
Study 27868385 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737
Study 27868385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study 26681191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat®) plus treatment as usual
Number of subjects: 0
Study 26681191 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 23385968 — intervention group
Group type: EXPERIMENTAL
Intervention: Having lunch
Number of subjects: 105
Study 23385968 — intervention group
Group type: COMPARATOR
Intervention: Skipping lunch
Number of subjects: 105
Study 21477658 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day buprenorphine patches plus oral paracetamol (5-25 μg/h buprenorphine patches plus 1000 mg oral paracetamol q.i.d.; n=110)
Number of subjects: 220
Study 21477658 — intervention group
Group type: COMPARATOR
Intervention: Co-codamol tablets (two 8/500-two 30/500 mg tablets q.i.d.; n=110)
Number of subjects: 220
Study 18985460 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chewing gum containing Lactobacillus reuteri (1 x 10(8) CFU/gum)
Number of subjects: 42
Study 18985460 — intervention group
Group type: EXPERIMENTAL
Intervention: Two active chewing gums
Number of subjects: 42
Study 18985460 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gums
Number of subjects: 42
Study 17581601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 75
Study 17581601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg (L)
Number of subjects: 75
Study 17581601 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (E)
Number of subjects: 75
Study 17581601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg plus Enalapril 20 mg (L/E)
Number of subjects: 75
Study 16281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase reverse transcriptase (TRT) expression in PCa
Number of subjects: 60
Study 16281501 — intervention group
Group type: COMPARATOR
Intervention: Telomerase reverse transcriptase (TRT) expression in BPH
Number of subjects: 60
Study 16281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) expression in PCa
Number of subjects: 60
Study 16281501 — intervention group
Group type: COMPARATOR
Intervention: Vascular endothelial growth factor (VEGF) expression in BPH
Number of subjects: 60
Study 16281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of TRT and VEGF expressions
Number of subjects: 60
Study 16281501 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TRT and VEGF expressions
Number of subjects: 60
Study 12487225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg daily)
Number of subjects: 69
Study 12487225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (1 mg/kg, twice daily)
Number of subjects: 69
Study 12487225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg, twice daily)
Number of subjects: 69
Study 12487225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9915661 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaspan (extended-release niacin) at a dosage of 2,000 mg/day
Number of subjects: 0
Study 9915661 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaspan (extended-release niacin)
Number of subjects: 0
Study 9915661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8563995 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible annuloplasty ring
Number of subjects: 184
Study 8563995 — intervention group
Group type: COMPARATOR
Intervention: Rigid annuloplasty ring
Number of subjects: 184
Study 8563995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of chordae tendineae
Number of subjects: 184
Study 8563995 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement without preservation of chordae tendineae
Number of subjects: 184
Study 8563995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 184
Study 8563995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 184
Study 8563995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with chordal preservation
Number of subjects: 184
Study 8563995 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement without chordal preservation
Number of subjects: 184
Study 2744295 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized protocol
Number of subjects: 222
Study 2744295 — intervention group
Group type: COMPARATOR
Intervention: Manual records
Number of subjects: 222
Study 941875 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised nonprofessional therapists
Number of subjects: 60
Study 941875 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional therapists
Number of subjects: 60
Study 941875 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised nonprofessional therapists
Number of subjects: 60
Study 941875 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study 31969287 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu decoction
Number of subjects: 49
Study 29127425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (804 mg/d)
Number of subjects: 20
Study 29127425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid (600 mg/d)
Number of subjects: 20
Study 29127425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27124606 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg/d in 2 divided doses)
Number of subjects: 102
Study 27124606 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 24067431 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 252
Study 24067431 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 252
Study 24067431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 24067431 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 252
Study 24067431 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin and Placebo
Number of subjects: 252
Study 21964738 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24
Study 21964738 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (MOD)
Number of subjects: 24
Study 21964738 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 19720213 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Chlorhexidine gluconate liquid for 7-15 days
Number of subjects: 17
Study 19720213 — intervention group
Group type: COMPARATOR
Intervention: Historical control (not specified)
Number of subjects: 17
Study 17241861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetomilast 25 mg
Number of subjects: 186
Study 17241861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetomilast 50 mg
Number of subjects: 186
Study 17241861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 16382433 — intervention group
Group type: EXPERIMENTAL
Intervention: SHTC (Internet-based self-help program for traumatic event-related consequences)
Number of subjects: 27
Study 16382433 — intervention group
Group type: COMPARATOR
Intervention: WL (Wait-list condition)
Number of subjects: 27
Study 12081827 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomoxir (600 mg total over 5 doses)
Number of subjects: 10
Study 12081827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10471167 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg daily)
Number of subjects: 8
Study 10471167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8687209 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based ORS
Number of subjects: 96
Study 8687209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum-based ORS
Number of subjects: 96
Study 8687209 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO ORS
Number of subjects: 96
Study 2225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg p.o.)
Number of subjects: 7
Study 2225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine plus lipid-heparin plus GHRH
Number of subjects: 7
Study 2225476 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 7
Study 511436 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy (6 to 8 exposures over 2 to 5 weeks)
Number of subjects: 38
Study 511436 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy (more intensive schedules)
Number of subjects: 38
Study 511436 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 38
Study 29792288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks (n=398)
Number of subjects: 1207
Study 29792288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks in FENO-high participants (n=97)
Number of subjects: 1207
Study 29792288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks in STRATOS 2 FENO-high population (n=108)
Number of subjects: 1207
Study 29792288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=400 in STRATOS 1, n=422 in STRATOS 2)
Number of subjects: 1207
Study 27083315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.3 mg administered preoperatively via lumbar puncture
Number of subjects: 78
Study 27083315 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppository (DS) 50 mg administered at the end of surgery
Number of subjects: 78
Study 27083315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 78
Study 24818609 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional retraining (AR)
Number of subjects: 60
Study 24818609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study 21875244 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty forecasts
Number of subjects: 0
Study 21875244 — intervention group
Group type: COMPARATOR
Intervention: Deterministic forecasts
Number of subjects: 0